ArticleEJHaem2026
Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma: Real-World Outcomes, Late Relapse Patterns, and Clinical Utility in the Chimeric Antigen Receptor T-Cell Era.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allogeneic hematopoietic cell transplantation (alloHCT) remains a curative option for relapsed or refractory (r/r) mantle cell lymphoma (MCL), although its role has shifted in the era of Bruton tyrosine kinase inhibition (BTKi) and chimeric antigen receptor T-cell (CAR-T) therapy. Real-world evidence on long-term outcomes and salvage strategies after relapse is limited. Methods: We performed a retrospective analysis of 29 patients with r/r MCL who underwent alloHCT between 2001 and 2017 using either higher-intensity or reduced-intensity conditioning. Outcomes assessed included overall survival (OS), progression-free survival (PFS), relapse incidence, and non-relapse mortality (NRM), focusing on relapse timing and management. Conditioning regimens were compared exploratorily. Results: With a median follow-up of 143 months (95% CI: 104-NR), 3-year OS and PFS were 41% and 34%, respectively. Relapse occurred in 38% of patients, including over one quarter with late (> 12-month), predominantly localized relapse. Salvage radiotherapy, alone or combined with BTKi, achieved durable disease control in about two-thirds of patients. Differences between higher-intensity and reduced-intensity conditioning were observed but remained exploratory and not statistically conclusive. Conclusion: In this real-world cohort, alloHCT provided sustained disease control for a subset of r/r MCL patients, including late, localized relapse amenable to salvage therapy. As alloHCT is now performed less frequently, such datasets are critical for decision-making in patients after CAR-T ineligibility or failure, especially where CAR-T access is limited. These findings support a continued, selective role for alloHCT in the modern treatment landscape and emphasize the need for real-world evidence to guide patient selection and sequencing in the CAR-T era. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.